# US 2008/0076975 A1 · Method and implantable device with reservoir array for pre-clinical in vivo testing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0076975 A1
- Document ID: US20080076975A1
- Status: Published application
- Kind: A1
- Application number: 11/831,772
- Filed: 2007-07-31
- Published: 2008-03-27
- Earliest claimed: 2005-01-25
- Assignees: MicroCHIPS, Inc.
- Inventors: John Santini; Dennis Ausiello
- Web page: https://patentgrep.com/patent/US20080076975A1

## CPC

- A61K 38/29: Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A61B 5/00: Measuring for diagnostic purposes (radiation diagnosis A61B6/00; diagnosis by ultrasonic, sonic or infrasonic waves A61B8/00); Identification of persons
- A61B 5/0031: {Implanted circuitry}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/0097: {Medicinal compositions released by microdevices, e.g. microelectromechanical systems [MEMS], microdevices comprising chips or microdevices on silicon}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61B 5/01: Measuring temperature of body parts {; Diagnostic temperature sensing, e.g. for malignant or inflamed tissue} (clinical contact thermometers G01K13/20)
- A61B 5/021: Measuring pressure in heart or blood vessels
- A61B 5/14503: {invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors (A61B5/1459, A61B5/1464, A61B5/1473, A61B5/1482, A61B5/14865 take precedence)}
- A61B 5/14532: {for measuring glucose, e.g. by tissue impedance measurement}
- A61B 5/14542: {for measuring blood gases (A61B5/14551 takes precedence)}
- A61F 2/82: Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents (stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07)
- A61F 2250/0068: the pharmaceutical product being in a reservoir
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

Methods of pre-clinical animal testing to monitor physiological parameters of test animals following exposure of molecules sealed in reservoirs on implanted devices. The test molecules are exposed to physiological fluid of the animal. The molecules can be configured as a sensor chemistry that reacts with the physiological fluid. The molecules can be a drug or drug candidate that is released into the animal. The test animals are non-human mammals.

## Claims

### Claim 1

A method of conducting a pre-clinical animal study comprising the steps of:
implanting into a non-human test animal a device which comprises:
a body portion,
a plurality of discrete reservoirs located in the body portion, each reservoir
having at least one opening,
molecules disposed within the reservoirs,
a plurality of discrete reservoir caps, each closing off the at least one
opening of each of the reservoirs, and
activation means for selectively disintegrating or permeabilizing each said
reservoir cap to expose the molecules in the reservoir;
exposing, via the activation means, at least a first amount of the molecules to a physiological fluid of the test animal; and
monitoring one or more physiological parameters of the test animal following exposing of the molecules.

### Claim 2 (depends on 1)

The method of claim 1, wherein at least one of the plurality of reservoirs is configured as a sensor, the molecules disposed within the reservoir defining a sensor chemistry,
said step of exposing exposes said sensor chemistry, and
said step of monitoring monitors a result of an interaction of said sensor chemistry with said physiological fluid.

### Claim 3 (depends on 1)

The method of claim 1, wherein said step of exposing the at least first amount of the molecules comprises releasing said molecules from at least one of the reservoirs into the test animal.

### Claim 4 (depends on 1)

The method of claim 1, wherein exposure of the molecules is initiated by a preprogrammed microprocessors or state machine, by wireless telemetry, and/or by feedback from one or more sensors.

### Claim 5 (depends on 2)

The method of claim 2, wherein the one or more sensors are implanted into the test animal.

### Claim 6 (depends on 5)

The method of claim 5, wherein a plurality of the sensors are sealed inside a second plurality of reservoirs until needed for sensing.

### Claim 7 (depends on 2)

The method of claim 2, wherein the one or more sensors are external to the body of the test animal.

### Claim 8 (depends on 1)

The method of claim 1, further comprising exposing a second amount of the molecules into the test animal, and further monitoring one or more physiological parameters of the test animal following the exposure of the second amount of the molecules.

### Claim 9 (depends on 3)

The method of claim 3, further comprising releasing a second amount of the molecules into the test animal, and further monitoring one or more physiological parameters of the test animal following the release of the second amount of the molecules.

### Claim 10 (depends on 9)

The method of claim 9, comprising changing the dose and/or dosing schedule of the first and second amounts of the molecules.

### Claim 11 (depends on 1)

The method of claim 1, wherein the molecules comprises a drug or drug candidate.

### Claim 12 (depends on 3)

The method of claim 3, wherein the molecules comprises a drug or drug candidate.

### Claim 13 (depends on 1)

The method of claim 1, wherein the molecules are chosen from the group of DNA, RNA, other nucleic acids, gene sequences or fragments, aptamers, other genetic material, and molecules that affect or modulate the expression of a gene.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the test animal is a mammal.

### Claim 16 (depends on 1)

The method of claim 1, wherein the test animal is selected from the group consisting of rats, dogs, cats, pigs, sheep, and non-human primates.
